X
[{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lighthouse Pharmaceuticals Announces Progression of LHP588 Clinical Development Program in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by Lighthouse Pharmaceuticals
Filters
Companies By Therapeutic Area
Details:
LHP588 is a Phase 2b, orally available small molecule, targets a specific, infectious pathogen, Porphyromonas gingivalis, associated with chronic degenerative and inflammatory disorders including dementia, periodontal disease, atherosclerosis, and orodigestive cancers.
Lead Product(s):
LHP588
Therapeutic Area: Neurology
Product Name: LHP588
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 10, 2023
Details:
Under the agreement, Lighthouse gains exclusive rights to develop, manufacture, and commercialize Quince’s legacy protease inhibitor portfolio including, COR588, COR388, COR852, and COR803 globally.
Lead Product(s):
COR588
Therapeutic Area: Neurology
Product Name: COR588
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Quince Therapeutics
Deal Size: $150.0 million
Upfront Cash: Undisclosed
Deal Type: Divestment
January 30, 2023